Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## 微創醫療科學有限公司\*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

## **CHANGE OF DIRECTORS**

The Board announces the following changes to the Board with effect from 30 August 2023:

- (1) Mr. Hongliang Yu has resigned as a non-executive Director;
- (2) Dr. Qiyi Luo has been appointed as a non-executive Director; and
- (3) Ms. Weiqin Sun has been appointed as a non-executive Director.

The board (the "Board") of directors (the "Director(s)") of MicroPort Scientific Corporation (the "Company", together with its subsidiaries, the "Group") announces the following changes to the Board with effect from 30 August 2023:

## **Resignation of Director**

(1) Mr. Hongliang Yu ("Mr. Yu") has resigned as a non-executive Director in order to devote more time to his other business endeavours. Mr. Yu has confirmed to the Company that he has no disagreement with the Board. The Company confirms that there is no matter relating to the resignation of Mr. Yu that needs to be brought to the attention of the shareholders of the Company.

The Company would like to express its gratitude to Mr. Yu for his valuable efforts and contributions to the Group during his term of office.

## **Appointment of Directors**

(2) Dr. Qiyi Luo (羅七一) ("**Dr. Luo**") has been appointed as a non-executive Director.

Dr. Luo, born in 1962, was the chief technology officer and a member of the Greater China Executive Committee and Intercontinental Cardiac Rhythm Management Committee of the Company. Dr. Luo joined the Group in January 2003, and has been mainly responsible for the technology, and research and development of the Group. Dr. Luo was appointed as a non-executive director and the chairman of MicroPort CardioFlow Medtech Corporation ("CardioFlow", a subsidiary of the Group listed on the Hong Kong Stock Exchange, stock code: 2160) in August 2019 and January 2020 respectively, and resigned from these positions in August 2023. From June 2019 to August 2023, Dr. Luo also served as a director of Shanghai MicroPort EP MedTech Co., Ltd. (an associate of the Group listed on the Science and Technology Board of Shanghai Stock Exchange, stock code: 688351).

Dr. Luo has over 32 years of experience in the medical device industry. He worked as the principal research and development engineer and a senior manufacturing/development engineer at Medtronic AVE Inc. from May 1995 to December 2002. From February 1991 to May 1995, he worked as a supervisor and an engineer of the angioplasty research and development team at Vas-Cath Inc., a subsidiary of C.R. Bard, Inc., a medical device manufacturing company listed on the New York Stock Exchange (ticker symbol: BCR).

Dr. Luo received his bachelor's degree in applied science from Yunnan University of Technology (雲南理工大學) in July 1983, his master's degree in applied science from Queen's University in Canada in December 1990 and his doctor's degree in biomedical engineering from University of Shanghai for Science and Technology (上海理工大學) in March 2015. Dr. Luo has been the inventor or the co-inventor of over 300 patents in China, the United States, Japan and the European Union.

Dr. Luo is interested in 9,802,432 shares/underlying shares, representing approximately 0.53% of the issued share capital of the Company as at the date of this announcement. Dr. Luo is also interested in 6,413,144 shares/underlying shares of CardioFlow, representing approximately 0.26% of its issued share capital, and 177,932 shares/underlying shares of MicroPort Cardiac Rhythm Management Limited, a subsidiary of the Company, representing approximately 0.10% of its issued share capital. Save as disclosed, Dr. Luo is not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance ("SFO").

Save as disclosed above, Dr. Luo has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

Dr. Luo will enter into a letter of appointment with the Company, subject to rotation and reelection at annual general meetings in accordance with the Articles of Association of the Company. Dr. Luo is entitled to receive emolument of RMB500,000 per year for serving as a non-executive Director, which was determined by the Board by reference to his experience and responsibilities and prevailing market conditions.

There is no information which is discloseable nor is Dr. Luo involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Dr. Luo that need to be brought to the attention of the shareholders of the Company.

(3) Ms. Weiqin Sun (孫維琴) ("Ms. Sun") has been appointed as a non-executive Director.

Ms. Sun, born in 1980, is currently the deputy general manager (in charge of overall management) of Shanghai Zhangjiang Technology Venture Capital Co., Ltd., the dean of Shanghai Zhangjiang Innovation Institute, and the deputy director of the investment service center of Shanghai Zhangjiang (Group) Co., Ltd.. Ms. Sun joined Shanghai Zhangjiang Group in July 2002. She has successively served as the assistant to the director of the incubator center of Shanghai Zhangjiang (Group) Co., Ltd., the executive deputy general manager (in charge of overall management), general manager of Shanghai Zhangjiang Business Incubator Management Co., Ltd., assistant general manager, deputy general manager of Shanghai Zhangjiang Technology Venture Capital Co., Ltd..

Ms. Sun graduated from Shanghai University with a bachelor's degree in Chinese language and literature in June 2002, and graduated from Fudan University with a master's degree in business administration in January 2010.

Ms. Sun is not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Ms. Sun has not held any directorship in any listed public companies in Hong Kong or overseas in the last three years, and she is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Listing Rules) of the Company, nor does she hold any other positions with the Company or any of its subsidiaries.

Ms. Sun will enter into a letter of appointment with the Company, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Ms. Sun will not receive any emolument for serving as a non-executive Director.

There is no information which is discloseable nor is Ms. Sun involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Ms. Sun that need to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Dr. Luo and Ms. Sun for joining the Board.

By Order of the Board

MicroPort Scientific Corporation

Dr. Zhaohua Chang

Chairman

Shanghai, the People's Republic of China, 30 August 2023

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun and Dr. Qiyi Luo; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

\* For identification purpose only